Beranda › Obesitas › New Jersey
Uji klinis Obesitas di New Jersey
20 studi untuk Obesitas mencari peserta di lokasi di New Jersey.
Kota di New Jersey
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Somerset
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07776509A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Hackensack University Medical Center, Hackensack
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Hypertension & Nephrology Association, Eatontown
- IMA Clinical Research Warren, Warren Township
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07282600A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Eatontown
- Research Site, Somerset
- Research Site, Warren Township
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- CardioMetabolic Collaborative Clinic, Somerset
Menerima pesertaFase 3
Usia 45 hingga 99 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- IMA Clinical Research Warren, Warren Township
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07321886A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Jersey City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Virtua Health Incorporated, Marlton
- Saint Michaels Medical Center, Newark
- CardioMetabolic Collaborative Clinic, Somerset
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07037459A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Clinical Research of Philadelphia, Pennington
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06897475A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Premier Research, Trenton
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Psoriasis Treatment Center of Central New Jersey, East Windsor
- Care Access - Hoboken, Hoboken
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06857942Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Premier Research, Trenton
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07684144A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Jersey City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Heart House - Vineland, Elmer
- Advanced Cardiology LLC - Hackettstown, Hackettstown
- The Heart House Haddon Heights, Haddon Heights
- dan 5 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07567001Metabolic Health, Bones and Nuts During Weight Loss in Adults
- Rutgers University - NJ Inst Food Nutrition & Health, New Brunswick
Menerima pesertaSukarelawan sehat diterima
Usia 50 hingga 75 · Semua jenis kelamin · Diperbarui 13 Mei 2026 · NCT06949280A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
- Vanda Investigational Site, Hamilton
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT07446439A Study of a Weight Loss Intervention in People With Endometrial Cancer
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
Menerima pesertaFase awal 1
Usia 18 ke atas · Wanita · Diperbarui 13 Apr 2026 · NCT06751589A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
- Frontage Clinical Services, Inc., Secaucus
Menerima pesertaFase 1
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT07465965Extracellular Vesicles, Insulin Action, and Exercise
- Institute for Food, Nutrition, and Health, New Brunswick
- Robert Wood Johnson University Hospital Clinical Research Center, New Brunswick
- Rutgers University Loree Gymnasium, New Brunswick
Menerima pesertaSukarelawan sehat diterima
Usia 30 hingga 80 · Semua jenis kelamin · Diperbarui 23 Jan 2026 · NCT06546085IVIG vs SCIG in CIDP
- Rutgers, The State University of New Jersey Clinical Research Center, New Brunswick
Menerima pesertaFase 1
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT05584631Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.